Zelia Gouveia

Dr. Zelia Gouveia

Honing Biosciences

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SRSusana Ramos
Susana Ramos
ACAna Rita Carlos
Ana Rita Carlos
BSBalamurugan Sundaram
Balamurugan Sundaram
VJViktória Jeney
Viktória Jeney
ARAna Ribeiro
Ana Ribeiro
MSMiguel P. Soares
Miguel P. Soares
Significance: Malaria, the disease caused by Plasmodium spp. infection, remains a major global cause of morbidity and mortality, claiming the lives of over ∼4.5 × 10 5 individuals per year. Paradoxically, however, up to 98% of infected individuals survive the infection, establishing disease tolerance to malaria. We found that this host defense strategy, which does not target Plasmodium directly, relies on the capacity of renal proximal tubule epithelial cells to detoxify labile heme, a pathologic by-product of hemolysis that accumulates in plasma and urine during the blood stage of infection. This defense strategy prevents the onset of acute kidney injury, a clinical hallmark of severe malaria.

11 September 2017 in The FEBS Journal
Verified
Journal Article
Open access
ZGZelia Gouveia
Zelia Gouveia
ACAna Rita Carlos
Ana Rita Carlos
XYXiaojing Yuan
Xiaojing Yuan
FSFrederico Aires Da Silva
Frederico Aires Da Silva
RSRoland Stocker
Roland Stocker
MSMiguel P. Soares
Miguel P. Soares
Extracellular hemoglobin, a byproduct of hemolysis, can release its prosthetic heme groups upon oxidation. This produces metabolically active heme that is exchangeable between acceptor proteins, macromolecules and low molecular weight ligands, termed here labile heme. As it accumulates in plasma labile heme acts in a pro‐oxidant manner and regulates cellular metabolism while exerting pro‐inflammatory and cytotoxic effects that foster the pathogenesis of hemolytic diseases. Here, we developed and characterized a panel of heme‐specific single domain antibodies (sdAbs) that together with a cellular‐based heme reporter assay, allow for quantification and characterization of labile heme in plasma during hemolytic conditions. Using these approaches, we demonstrate that when generated during hemolytic conditions labile heme is bound to plasma molecules with an affinity higher than 10−7 m and that 2–8% (~ 2–5 μm) of the total amount of heme detected in plasma can be internalized by bystander cells, termed here bioavailable heme. Acute, but not chronic, hemolysis is associated with transient reduction of plasma heme‐binding capacity, that is, the ability of plasma molecules to bind labile heme with an affinity higher than 10−7 m. The heme‐specific sdAbs neutralize the pro‐oxidant activity of soluble heme in vitro, suggesting that these maybe used to counter the pathologic effects of labile heme during hemolytic conditions. Finally, we show that heme‐specific sdAbs can be used to visualize cellular heme. In conclusion, we describe a panel of heme‐specific sdAbs that when used with other approaches provide novel insights to the pathophysiology of heme.

31 October 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SLSheila López-Cobo
Sheila López-Cobo
JFJaime R. Fuentealba
Jaime R. Fuentealba
PGPaul Gueguen
Paul Gueguen
PBPierre-Emmanuel Bonté
Pierre-Emmanuel Bonté
KTKyriaki Tsalkitzi
Kyriaki Tsalkitzi
SASebastian Amigorena
Sebastian Amigorena
Failure of adoptive T-cell therapies in patients with cancer is linked to limited T-cell expansion and persistence, even in memory-prone 41BB-(BBz)–based chimeric antigen receptor (CAR) T cells. We show here that BBz-CAR T-cell stem/memory differentiation and persistence can be enhanced through epigenetic manipulation of the histone 3 lysine 9 trimethylation (H3K9me3) pathway. Inactivation of the H3K9 trimethyltransferase SUV39H1 enhances BBz-CAR T cell long-term persistence, protecting mice against tumor relapses and rechallenges in lung and disseminated solid tumor models up to several months after CAR T-cell infusion. Single-cell transcriptomic (single-cell RNA sequencing) and chromatin opening (single-cell assay for transposase accessible chromatin) analyses of tumor-infiltrating CAR T cells show early reprogramming into self-renewing, stemlike populations with decreased expression of dysfunction genes in all T-cell subpopulations. Therefore, epigenetic manipulation of H3K9 methylation by SUV39H1 optimizes the long-term functional persistence of BBz-CAR T cells, limiting relapses, and providing protection against tumor rechallenges. Significance: Limited CAR T-cell expansion and persistence hinders therapeutic responses in solid cancer patients. We show that targeting SUV39H1 histone methyltransferase enhances 41BB-based CAR T-cell long-term protection against tumor relapses and rechallenges by increasing stemness/memory differentiation. This opens a safe path to enhancing adoptive cell therapies for solid tumors. See related article by Jain et al., p. 142. This article is featured in Selected Articles from This Issue, p. 5

17 November 2009 in Physiologia Plantarum
Verified
Journal Article
Closed access
PDF file
José Hélio CostaJosé Hélio Costa
José Hélio Costa
DMDirce Fernandes De Melo
Dirce Fernandes De Melo
ZGZelia Gouveia
Zelia Gouveia
HÉLIA CARDOSOHÉLIA CARDOSO
HÉLIA CARDOSO
Augusto PeixeAugusto Peixe
Augusto Peixe
BABirgit Arnholdt-Schmitt
Birgit Arnholdt-Schmitt

10 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
NANagjie Alijaj
Nagjie Alijaj
SMSandrine Moutel
Sandrine Moutel
ZGZelia Gouveia
Zelia Gouveia
MGMaxim Gray
Maxim Gray
MRMaurizio Roveri
Maurizio Roveri
Michele BernasconiMichele Bernasconi
Michele Bernasconi
The fibroblast growth factor receptor 4 (FGFR4) is overexpressed in rhabdomyosarcoma (RMS) and represents a promising target for treatments based on specific and efficient antibodies. Despite progress, there is an urgent need for targeted treatment options to improve survival rates, and to limit long-term side effects. From phage display libraries we selected FGFR4-specific single-domain antibodies (sdAb) binding to recombinant FGFR4 and validated them by flow cytometry, surface plasmon resonance, and fluorescence microscopy. The specificity of the selected sdAb was verified on FGFR4-wild type and FGFR4-knock out cells. FGFR4-sdAb were used to decorate vincristine-loaded liposomes and to generate chimeric antigen receptor (CAR) T cells. First, incubation of RMS cells with FGFR4-sdAb revealed that FGFR4-sdAb can block FGF19-FGFR4 signaling via the MAPK pathway and could therefore serve as therapeutics for FGFR4-dependent cancers. Second, FGFR4-targeted vincristine-loaded liposomes bound specifically to RMS cells and were internalized by the receptor, demonstrating the potential for active drug delivery to the tumor. Third, FGFR4-CAR T cells, generated with one sdAb candidate, demonstrated strong and specific cytotoxicity against FGFR4 expressing RMS cells. We selected novel FGFR4-sdAb with high specificity and nano- to picomolar affinities for FGFR4 which have the potential to enable multiple FGFR4-targeted cancer therapy approaches.

1 September 2019 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
FEFranziska A. Englert
Franziska A. Englert
RSRaphael A. Seidel
Raphael A. Seidel
KGKerstin Galler
Kerstin Galler
ZGZelia Gouveia
Zelia Gouveia
MSMiguel P. Soares
Miguel P. Soares
SWSebastian Weis
Sebastian Weis